Preparation of Piyanling Liniment and comparative evaluation of clinical efficacy of Piyanling Liniment versus Halcinonide Solution in the treatment of neurodermatitis

Background Neurodermatitis, a prevalent neuropsychiatric dermatological disorder, is characterized by severe and paroxysmal pruritus, as well as skin lichenification. This chronic condition follows a prolonged and progressive course, with recurring episodes that persist for several years without resolution. Furthermore, there is a significant probability of relapse after remission, greatly affecting the patients’ quality of life and overall satisfaction. Aims This study aims to formulate Piyanling Liniment and evaluate its clinical efficacy in comparison with Halcinonide Solution for the treatment of neurodermatitis. Patients and methods Piyanling Liniment, a prescription formulation incorporating resorcinol, salicylic acid, fluocinolone acetate, and borneol as its primary constituents, was formulated. A randomized controlled trial was conducted involving 100 patients diagnosed with neurodermatitis seeking treatment at the outpatient dermatology department of our hospital. The patients were divided into two groups: the Piyanling Liniment group, comprising 50 patients treated with Piyanling Liniment, and the Halcinonide Solution group, comprising 50 patients treated with Halcinonide Solution. Both groups applied the respective treatments twice daily at a dosage of 0.5 ml/cm 2 . Clinical symptoms, including the skin lesion area, skin lesion degree, pruritus degree, and pigmentation degree, were assessed before treatment and after 4, 7, 10, and 14 days of treatment to evaluate therapeutic efficacy and compare the occurrence of adverse drug reactions. Results After 14 days of treatment, it was observed that Piyanling Liniment exhibited superior therapeutic efficacy in terms of reducing skin lesions, alleviating pruritus, and restoring pigmentation compared with Halcinonide Solution, with a total effective rate of 98.0 and 92.0% in the respective groups. The occurrence of adverse drug reactions was 4.0 and 2.0% in the Piyanling Liniment and Halcinonide Solution groups, respectively. Based on the comprehensive analysis, a significant statistical difference in treatment outcomes was observed between the two patient cohorts ( P <0.05). However, no significant disparity was detected in terms of the occurrence of adverse drug reactions between the two groups ( P >0.05). Conclusion The formulation procedure of Piyanling Liniment is uncomplicated, demonstrating a favorable safety profile and noteworthy efficacy in the treatment of neurodermatitis. Piyanling Liniment demonstrates promising clinical outcomes, primarily through the reduction of skin lesions, alleviation of pruritus, and restoration of pigmentation. Consequently, it presents itself as a viable therapeutic option for individuals seeking relief from symptoms associated with neurodermatitis.